Tisagenlecleucel Submitted for European Approval for ALL, DLBCL

November 6, 2017 – The European Medicines Agency (EMA) has received a Marketing Authorization Application (MAA) for tisagenlecleucel for 2 forms of advanced lymphoma. Novartis is seeking approval to market tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and for adult patients with relapsed/refractory diffuse large B-cell lymphoma … (leggi tutto)